CAS 2206736-04-9

MRTX-1257

CAS : 2206736-04-9

MRTX-1257: selective, irreversible KRAS G12C inhibitor; IC50 of 900 pM; 31% bioavailable in mice; 77% target engagement.

Formule : C₃₃H₃₉N₇O₂

Degré de pureté : 97.3% - 99.07%

Couleur et forme : Solid

Masse moléculaire : 565.71

Ref: TM-T16143

(2S)-1-(1-Oxo-2-propen-1-yl)-4-[5,6,7,8-tetrahydro-7-(8-methyl-1-naphthalenyl)-2-[[(2S)-1-methyl-2-pyrrolidinyl]methoxy]pyrido[3,4-d]pyrimidin-4-yl]-2-piperazineacetonitrile

CAS : 2206736-04-9

Formule : C₃₃H₃₉N₇O₂

Degré de pureté : 98%

Couleur et forme : Solid

Masse moléculaire : 565.7085

Ref: IN-DA01KJSQ

MRTX-1257

CAS : 2206736-04-9

MRTX-1257

Degré de pureté : ≥95%

Masse moléculaire : 565.71g/mol

Ref: 54-BUP09493

MRTX-1257

CAS : 2206736-04-9

MRTX-1257 is an inhibitor of protein tyrosine phosphatases, which are enzymes that dephosphorylate proteins on the surface of cells. MRTX-1257 is a covalent inhibitor that binds to the active site of these enzymes and prevents them from dephosphorylating specific proteins. This mechanism has been shown to have immunomodulatory effects in tumor tissue and to be effective against cancer. In addition, MRTX-1257 has been shown to inhibit pancreatic cancer growth in a mouse model. It also inhibits tumor cell proliferation by binding to cell receptors or altering their function.

Formule : C₃₃H₃₉N₇O₂

Degré de pureté : Min. 95%

Masse moléculaire : 565.71 g/mol

Ref: 3D-GND73604